Search
Prostatic Neoplasms Clinical Trials
A listing of 20 Prostatic Neoplasms clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 12 of 20
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Prostatic Neoplasms
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
There are currently 20 active clinical trials seeking participants for Prostatic Neoplasms research studies. The states with the highest number of trials for Autism participants are California, New York, Ontario and Texas.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Healthy Volunteer Trials
Recruiting
Healthy volunteer trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
Healthy
Healthy Volunteers
Collection of Blood From Patients With Prostate Cancer
Recruiting
Background:
It is not fully understood why prostate cancer in some men becomes androgen-independent (no longer responds to anti-androgen medication), but genetics likely plays an important role.
Genes contain the hereditary information that is passed down from parents to children. Although everyone has the same set of genes, individuals can have different forms of the same gene.
Differences in genes may explain, at least in part, why some people develop a more aggressive form of prostate cancer... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
04/24/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Prostatic Neoplasms, Cancer Of Prostate, Prostate Cancer, Metastatic Prostate Cancer, Prostate
A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer
Recruiting
The main purpose of this study is to determine if the addition of apalutamide to radiotherapy (RT) plus luteinizing hormone-releasing hormone agonist (LHRHa) delays metastatic progression as assessed by prostate specific membrane antigen-positron emission tomography (PSMA-PET) or death compared with RT plus LHRHa alone.
Gender:
Male
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Arizona Urology Specialists, Tucson, Arizona +138 locations
Conditions: Prostatic Neoplasms
A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer
Recruiting
The purpose of this study is to determine the recommended phase 2 dose(s) (RP2Ds) of JNJ-78278343 in Part 1 (Dose Escalation) and the safety at the RP2Ds in Part 2 (Dose Expansion).
Gender:
Male
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Columbia University Medical Center Herbert Irving Pavilion, New York, New York +10 locations
Conditions: Prostatic Neoplasms
Imaging Studies to Check the Local Response of Prostate Cancer to Radiation Therapy
Recruiting
Background:
- Radiation is a common treatment for prostate cancer. It helps damage tumor cells and causes them to die. Radiation can be effective, but some tumors may be harder to treat with radiation or even with surgery. This happens to a small number of men who have either radiation or surgery for prostate cancer. Most men who have these hard-to-treat tumors do not know if the tumor has recurred only in the prostate or has spread to another area. Also, men whose prostate cancer has recurred... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
04/17/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Prostatic Neoplasms, Prostate Cancer
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
Recruiting
The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.
Gender:
Male
Ages:
18 years and above
Trial Updated:
04/16/2024
Locations: NorthShore University Health System, Glenview, Illinois +3 locations
Conditions: Prostate Cancer, Prostatic Neoplasms
Men at High Genetic Risk for Prostate Cancer
Recruiting
Background:
Research studies have shown that genetic changes and family history may increase a man s risk for prostate cancer. Researchers want to follow the prostate health of men who have specific genetic changes associated with prostate cancer to help them learn more about which men are at higher risk for prostate cancer.
Objectives:
To study men with specific genetic changes and determine who is at higher risk for getting prostate cancer. To study if certain genetic changes and family his... Read More
Gender:
Male
Ages:
Between 30 years and 75 years
Trial Updated:
04/16/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Prostatic Neoplasms
A Study of MK-5684 Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Recruiting
The purpose of this study is to assess the efficacy and safety of MK-5684 plus hormone replacement therapy (HRT) compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) previously treated with one next-generation hormonal agent (NHA). The primary study hypotheses are that MK-5684 is superior to alternative abiraterone acetate or enzalutamide with respect to radiographic progression free survival (rPFS) per Prostate... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/10/2024
Locations: Emad Ibrahim,MD,INC. ( Site 0012), Redlands, California +42 locations
Conditions: Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
Study of Rates of Prostate Cancer Diagnosis in Men of African Ancestry Using MRI and MRI Guided Biopsy
Recruiting
Background:
Prostate cancer (PCa) is one of the most common cancers in American men; it is a leading cause of death. Men of African ancestry have a higher rate of prostate cancer, and a higher likelihood of death, compared to men of European ancestry. The reasons for these higher rates are not known; they may include genetic and environmental factors. Better screening methods are needed.
Objective:
To test an imaging technology called multiparametric magnetic resonance imaging (mpMRI) for det... Read More
Gender:
Male
Ages:
Between 35 years and 120 years
Trial Updated:
03/30/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Prostate Specific Antigens, Positive Digital Rectal Examination, Strong Family History of Prostate Cancer, Prostatic Neoplasms
Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer
Recruiting
The purpose of this study is to assess the safety, tolerability and preliminary efficacy of CC-94676 in men with progressive metastatic castration resistant prostate cancer.
Gender:
Male
Ages:
18 years and above
Trial Updated:
03/29/2024
Locations: Local Institution - 118, Birmingham, Alabama +26 locations
Conditions: Prostatic Neoplasms
A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
Recruiting
The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D[s]) of JNJ-69086420 in Part 1 (Dose Escalation) and to determine safety and preliminary signs of clinical activity at the RP2D(s) in Part 2 (Dose Expansion).
Gender:
Male
Ages:
18 years and above
Trial Updated:
03/26/2024
Locations: City of Hope, Duarte, California +6 locations
Conditions: Prostatic Neoplasms, Adenocarcinoma
A Study of JNJ-80038114 in Participants With Advanced Stage Prostate Cancer
Recruiting
The purpose of this study is to determine recommended phase 2 dose(s) (RP2Ds) of JNJ-80038114 in Part 1 (dose escalation) and to determine the safety at the RP2D(s) in Part 2 (dose expansion).
Gender:
Male
Ages:
18 years and above
Trial Updated:
03/26/2024
Locations: University Of Minnesota, Minneapolis, Minnesota +5 locations
Conditions: Prostatic Neoplasms
64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 (COMBAT)
Recruiting
The aim for this study is to determine the safety and efficacy of 67Cu-SAR-BBN in participants with Gastrin Releasing Peptide Receptor (GRPR)-expressing metastatic castrate resistant prostate cancer in patients who are ineligible for therapy with 177Lu-PSMA-617.
Gender:
Male
Ages:
18 years and above
Trial Updated:
03/26/2024
Locations: Stanford University, Stanford, California +5 locations
Conditions: Prostatic Neoplasms, Castration-Resistant
1 - 12 of 20